Molecular genetics of sarcomas: Applications to diagnoses and therapy

Cancer Science

Volumn 100, Issue 9, 2009, Pages 1573-1580

  Toguchida, Junya ^a,b,c   Nakayama, Tomitaka ^c  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC PROCEDURE; GENETICS; HUMAN; MOLECULAR BIOLOGY; REVIEW; SARCOMA;

HUMANS; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSTIC TECHNIQUES; SARCOMA;

EID: 70149121143     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01232.x     Document Type: Review

References (66)

1. Fletcher CD, van den Berg E, Molenaar WM. Pleomorphic malignant fibrous histiocytoma/undifferentiated high grade pleomorphic sarcoma. In: Fletcher CD, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Washington, DC: IARC Press, 2002; 120-2.
2. Delattre O, Zucman J, Plougastel B et al. Gene fusion with an ETS DNAbinding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162-5.
3. Law WJ, Cann KL, Hicks GG. TLS, EWS and TAF15: a model for transcriptional integration of gene expression. Brief Funct Genomic Proteomic 2006; 5: 8-14.
4. de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000; 18: 204-13.
5. Zucman J, Delattre O, Desmaze C et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 1993; 4: 341-5.
6. Waters BL, Panagopoulos I, Allen EF. Genetic characterization of angiomatoid fibrous histiocytoma identifies fusion of the FUS and ATF-1 genes induced by a chromosomal translocation involving bands 12q13 and 16p11. Cancer Genet Cytogenet 2000; 121: 109-16.
7. Fujimura Y, Ohno T, Siddique H, Lee L, Rao VN, Reddy ES. The EWSATF- 1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator. Oncogene 1996; 12: 159-67.
8. Tachibana M, Takeda K, Nobukuni Y et al. Ectopic expression of MITF, a gene for Waardenburg syndrome type 2, converts fibroblasts to cells with melanocyte characteristics. Nat Genet 1996; 14: 50-4.
9. Davis IJ, Kim JJ, Ozsolak F et al. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell 2006; 9: 473-84.
10. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307-16.
11. Lamballe F, Klein R, Barbacid M. trkC, a new member of the trk family of tyrosine protein kinase, is a receptor for neurotrophin-3. Cell 1991; 66: 967- 79.
12. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PHB. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998; 18: 184-7.
13. Thaete C, Brett D, Monaghan P et al. Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum Mol Genet 1999; 8: 585-91.
14. Perani M, Ingram CJ, Cooper CS, Garrett MD, Goodwin GH. Conserved SNH domain of the proto-oncoprotein SYT interacts with components of the human chromatin remodeling complexes, while the QPGY repeat domain forms homo-oligomers. Oncogene 2003; 22: 8156-67.
15. Gure AO, Türeci O, Sahin U et al. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer 1997; 72: 965-71.
16. de Bruijin DRH, Nap J-P, van Kessel AG. The (Epi) genetics of human synovial sarcoma. Genes Chromosomes Cancer 2007; 46: 107-17.
17. Simon MP, Pedeutour F, Sirvent N et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997; 15: 95-8.
18. Subramanian S, West RB, Corless CL et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 2004; 23: 7780-90.
19. Kingston RE, Narlikar GJ. ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev 1999; 13: 2339-52.
20. Versteege I, Sévenet N, Lange J et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998; 394: 203-6.
21. Modena P, Lualdi E, Facchinetti F et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res 2005; 65: 4012-9.
22. Kohashi K, Izumi T, Oda Y et al. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol 2009; 40: 349-55.
23. Sato Y, Nabeta Y, Tsukahara T et al. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24 (+) patients with synovial sarcoma. J Immunol 2002; 169: 1611-8.
24. Kawaguchi S, Wada T, Ida K et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 2005; 3: 1.
25. Nakatani F, Tanaka K, Sakimura R et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 2003; 278: 15105-15.
26. Matsunobu T, Tanaka K, Matsumoto Y et al. The prognostic and therapeutic relevance of p27kip1 in Ewing's family tumors. Clin Cancer Res 2004; 10: 1003-12.
27. Li X, Tanaka K, Nakatani F et al. Transactivation of cyclin E gene by EWSFli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells. Int J Cancer 2005; 116: 385-94.
28. Nishimori H, Sasaki Y, Yoshida K et al. The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene 2002; 21: 8302-9.
29. Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS ONE 2008; 3: e1965.
30. Allander SV, Illei PB, Chen Y et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002; 161: 1587-95.
31. Nagayama S, Katagiri T, Tsunoda T et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 2002; 62: 5859-66.
32. Fukukawa C, Hanaoka H, Nagayama S et al. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci 2008; 99: 432-40.
33. Friend SH, Bernards R, Rogelj S. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643-6.
34. Wadayama B, Toguchida J, Shimizu T et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 1994; 54: 3042-8.
35. Li FP, Fraumeni JF Jr. Prospective study of a family cancer syndrome. JAMA 1982; 247: 2692-4.
36. Malkin D, Li FP, Strong LC, Fraumeni JF Jr. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-8.
37. Toguchida J, Yamaguchi T, Ritchie B et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992; 52: 6194-9.
38. Walkley CR, Qudsi R, Sankaran VG et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Gene Dev 2008; 22: 1662-76.
39. Hanada K, Hickson D. Molecular genetics of RecQ helicase disorders. Cell Mol Life Sci 2007; 64: 2306-22.
40. Wang LL, Gannavarapu A, Kozinetz CA et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothumund- Thomson syndrome. J Natl Cancer Inst 2003; 95: 669-74.
41. Nishijo K, Nakayama T, Aoyama T et al. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer 2004; 111: 367-72.
42. Wei G, Lonardo F, Ueda T et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 1999; 80: 199-204.
43. Maelandsmo GM, Berner JM, Florences VA et al. Homozygous deletion frequency and expression level of the CDKN2 gene in human sarcomas - relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 1995; 72: 393-8.
44. Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 1997; 79: 1541-7.
45. Haydon RC, Deyrup A, Ishikawa A et al. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 2002; 102: 338-42.
46. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DPM. Critical role of Notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008; 14: 2962-9.
47. Warzecha J, Göttig S, Chow KU et al. Inhibition of osteosarcoma cell proliferation by the Hedgehog-inhibitor cyclopamine. J Chemother 2007; 19: 554-61.
48. Levine RA, Forest T, Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol 2002; 39: 372-8.
49. Coltella N, Manara MC, Cerisano UV. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J 2003; 17: 1162-4.
50. Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle 2008; 7: 965-70.
51. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrinmediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005; 65: 2406-11.
52. McClatchey AI, Saotome I, Mercer K et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 1998; 12: 1121-33.
53. Huang W, Chang HY, Fei T, Wu H, Chen Y-G. GSKΒ mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene 2007; 26: 2471-82.
54. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932-40.
55. Lee YF, John M, Edwards S et al. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer 2003; 88: 510-5.
56. Nakayama R, Nemoto T, Takahashi H et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 2007; 20: 749-59.
57. Nielsen TO, West RB, Linn SC et al. Molecular characterization of soft tissue tumours: a gene expression study. Lancet 2002; 359: 1301-7.
58. Lee YF, John M, Falconer A et al. A gene expression signature associated with metastatic outcome in human leiomyosarcomas. Cancer Res 2004; 64: 7201-4.
59. Riggi N, Suvà ML, Suvà D et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008; 68: 2176-85.
60. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007; 11: 421-9.
61. Riggi N, Cironi L, Provero P et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 2006; 66: 7016-23.
62. Perez-Losada J, Pintado B, Gutierrez-Adan A et al. The chimeric FUS/TLSCHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene 2000; 19: 2413-22.
63. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. Alveolar rhabdomyosarcomas in conditional Pax3: Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004; 18: 2614-26.
64. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007; 11: 375-88.
65. Segal NH, Pavlidis P, Antonescu CR et al. Classification and subtype prediction of adult soft tissues by functional genomics. Am J Pathol 2003; 163: 691-700.
66. Baird K, Davis S, Antonescu CR et al. Gene expression profiling of human sarcomas: Insights into sarcoma biology. Cancer Res 2005; 65: 9226-35.